A similar P2Y2R agonist, denufosol, improved lung function relative to placebo in cystic fibrosis patients during phase 2 clinical trials, but failed to achieve its primary endpoints during phase 3 follow-up trials (Accurso et al., 2011). This evidence concerns the gene P2RY2 and cystic fibrosis.